NR1I2 and triple-negative breast carcinoma: showed that FBI-1 can inhibit the activity of SP1 in triple negative breast cancer (TNBC) cells, downregulate the expression of miR-30c, and then upregulate the expression of PXR, and ultimately accelerate the antitumor drug Olaparib’s metabolism and clearance rate to induce cell resistance (62).